$57.15
0.61% today
Nasdaq, Aug 12, 04:44 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$56.80
-1.30 2.24% 1M
-6.75 10.62% 6M
-8.93 13.59% YTD
-32.23 36.20% 1Y
-38.27 40.25% 3Y
-60.03 51.38% 5Y
-79.22 58.24% 10Y
+48.58 591.00% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.53 0.92%

Key metrics

Basic
Market capitalization
$10.9b
Enterprise Value
$10.1b
Net debt
positive
Cash
$1.4b
Shares outstanding
192.0m
Valuation (TTM | estimate)
P/E
17.1 | 16.1
P/S
3.6 | 3.4
EV/Sales
3.3 | 3.1
EV/FCF
14.6
P/B
1.8
Financial Health
Equity Ratio
81.0%
Return on Equity
7.5%
ROCE
12.3%
ROIC
11.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$3.1b | $3.2b
EBITDA
$853.8m | $905.2m
EBIT
$829.4m | $831.1m
Net Income
$657.2m | $675.9m
Free Cash Flow
$691.2m
Growth (TTM | estimate)
Revenue
18.4% | 12.3%
EBITDA
165.4% | 47.6%
EBIT
198.5% | 45.8%
Net Income
156.1% | 58.4%
Free Cash Flow
224.7%
Margin (TTM | estimate)
Gross
79.6%
EBITDA
27.9% | 28.2%
EBIT
27.1%
Net
21.5% | 21.1%
Free Cash Flow
22.6%
More
EPS
$3.3
FCF per Share
$3.6
Short interest
4.1%
Employees
3k
Rev per Employee
$940.0k
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Biomarin Pharmaceutical forecast:

28x Buy
80%
7x Hold
20%

Analyst Opinions

35 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
80%
Hold
20%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,064 3,064
18% 18%
100%
- Direct Costs 626 626
21% 21%
20%
2,437 2,437
18% 18%
80%
- Selling and Administrative Expenses 905 905
5% 5%
30%
- Research and Development Expense 678 678
14% 14%
22%
854 854
165% 165%
28%
- Depreciation and Amortization 24 24
44% 44%
1%
EBIT (Operating Income) EBIT 829 829
199% 199%
27%
Net Profit 657 657
156% 156%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Positive
Seeking Alpha
7 days ago
BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition brings late-stage BMN 401 for ENPP1 deficiency, with pivotal phase 3 data expected in 1H 2026 and potential first-mover advantage. Voxzogo and Palynziq continue to drive growth, with label expansions and new pipeline candidates like BMN 3...
Neutral
Seeking Alpha
7 days ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Alexander Hardy - President, CEO & Director Brian R. Mueller - Executive VP of Finance & CFO Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Traci McCarty - Group Vice President Conference Ca...
Positive
The Motley Fool
8 days ago
BioMarin (BMRN) Q2 Revenue Jumps 16%
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,040
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today